Careers  |  Sign In  |  Register  |   Twitter

Latest in Resource Center: Diabetes

By Anne Harding NEW YORK (Reuters Health) – Allopurinol reduces left ventricular hypertrophy (LVH) in type 2 diabetics with well-controlled blood pressure, new findings show. From 40% to 70% of type 2 diabetics have LVH, which independently increases the risk of cardiovascular events, cardiovascular...
By Ben Hirschler AMSTERDAM (Reuters) – The dipeptidyl peptidase 4 (DPP-4) class of drugs got a mixed safety report on Monday as studies showed they did not raise the risk of heart attacks but might be linked to heart failure. Reassuringly, the medicines were not associated with increased rates of...
NEW YORK (Reuters Health) – The dipeptidyl peptidase-4 (DPP4) inhibitor linagliptin was safe and effective for lowering glycated hemoglobin (HbA1c) in a controlled trial of elderly patients with poorly controlled type 2 diabetes. Studies of glucose-lowering treatments in elderly diabetics and of the...
123